Evelo Biosciences Stock Shares Owned By Institutions
| EVLODelisted Stock | USD 8.23 2.68 24.56% |
Evelo Biosciences fundamentals help investors to digest information that contributes to Evelo Biosciences' financial success or failures. It also enables traders to predict the movement of Evelo Pink Sheet. The fundamental analysis module provides a way to measure Evelo Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evelo Biosciences pink sheet.
Evelo |
Evelo Biosciences Company Shares Owned By Institutions Analysis
Evelo Biosciences' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Evelo Biosciences Shares Owned By Institutions | 83.13 % |
Most of Evelo Biosciences' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 83% of Evelo Biosciences are shares owned by institutions. This is 86.22% higher than that of the Biotechnology sector and 75.01% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 112.01% lower than that of the firm.
Evelo Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evelo Biosciences' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evelo Biosciences could also be used in its relative valuation, which is a method of valuing Evelo Biosciences by comparing valuation metrics of similar companies.Evelo Biosciences is currently under evaluation in shares owned by institutions category among its peers.
Evelo Fundamentals
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 83.13 % | ||||
| Number Of Shares Shorted | 430.1 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) | ||||
| Net Income | (114.53 M) | ||||
| Cash And Equivalents | 92.01 M | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 51.14 M | ||||
| Debt To Equity | 1.55 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (101.23 M) | ||||
| Short Ratio | 0.42 X | ||||
| Earnings Per Share | (15.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 66 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 7 M | ||||
| Total Asset | 64.44 M | ||||
| Retained Earnings | (529.22 M) | ||||
| Working Capital | 39.18 M | ||||
| Current Asset | 49.29 M | ||||
| Current Liabilities | 4.32 M | ||||
| Z Score | -16.24 | ||||
| Net Asset | 64.44 M |
About Evelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evelo Pink Sheet
Moving against Evelo Pink Sheet
| 0.77 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.63 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.62 | DTIL | Precision BioSciences | PairCorr |
| 0.44 | VALN | Valneva SE ADR | PairCorr |
| 0.44 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |